Openbookopenbook
Equity
DCTH
+0.0 · +0.00%
USD · NASDAQ

Delcath Systems Inc(DCTH) Stock Analysis | Healthcare

USD --+0.00%
Reward67High
Risk18Low
75%Data
Thin 1% profit margin · Revenue growing 21% YoY
Growth Machine
Market Cap:594.74M
ⓘ
Reward Rating
67
High
Reward Assessment
75% data coverage
Top 25% of stocksView factors
ⓘ
Risk Rating
18
Low
Risk Assessment

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on DCTH to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for DCTH, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $24.00.

What is Delcath Systems Inc?

, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.

DCTH · Verdict

Solid reward · low risk

DCTH stands out on balance sheet and growth, but watch the valuation signal.

Based on 88% data coverage

DCTH · Verdict

What’s working & what to watch

Strengths 4

  • Balance sheet100/100

    Current ratio 10.92

  • Growth92/100

    Revenue +215.3% CAGR

  • Volatility80/100

    Top decile vs peers

  • Cash flow74/100

    25% free-cash-flow margin

Watchouts 1

  • Valuation39/100

    P/E 25.8× · PEG 1.60

Model-based scoring. For information only — not financial advice.

What is Delcath Systems Inc?

, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 594.74M, and a P/E ratio of 1714.0x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: High (67)

The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

BWAYSmall Cap / 592M market cap
Brainsway Ltd
Compare
XVIPFSmall Cap / 608M market cap
Xvivo Perfusion AB (publ)
Compare
CERSSmall Cap / 566M market cap
Cerus Corporation
Compare
Company Information
SectorHealthcare
IndustryMedical Devices
Market Cap594.74M
P/E Ratio1714
Dividend YieldN/A
Beta0.523
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.